Infection and inflammation-induced proatherogenic changes of lipoproteins

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Khovidhunkit, Weerapan ^a   Memon, Riaz A ^a   Feingold, Kenneth R ^a   Grunfeld, Carl ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMYLOID A PROTEIN; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPASE A2; PHOSPHOLIPID TRANSFER PROTEIN; SPHINGOLIPID; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; ATHEROGENESIS; ATHEROMA; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; INFLAMMATION; LIPID METABOLISM; LIPID OXIDATION; PRIORITY JOURNAL;

EID: 0034125220     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315611     Document Type: Conference Paper

References (110)

1. 1. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116:273-8.
2. 2. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis, Eur Heart J 1993; 14(suppl K):30-8.
3. 3. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71:437-9.
4. 4. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. BMJ 1993; 306: 688-91.
5. 5. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348:567-72.
6. 6. Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis 1976; 29: 459-67.
7. 7. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y. Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 1999; 8:220-6.
8. 8. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99:469-75.
9. 9. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731-3.
10. 10. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237-42.
11. 11. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007-11.
12. 12. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96:4095-103.
13. 13. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-54.
14. 14. Hardardóttir I, Grünfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994; 5:207-15.
15. 15. Sammalkorpi K. Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988; 37:859-65.
16. 16. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-52.
17. 17. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76:1423-7.
18. 18. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998; 19(suppl A):A24-30.
19. 19. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52:223-61.
20. 20. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
21. 21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7.
22. 22. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-9.
23. 23. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22.
24. 24. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81:7B-12B.
25. 25. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882-8.
26. 26. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989; 321:1311-6.
27. 27. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-45.
28. 28. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-8.
29. 29. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-24.
30. 30. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94:350-6.
31. 31. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32:1741-53.
32. 32. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990;31:1387-98.
33. 33. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276:875-81.
34. 34. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:69-75.
35. 35. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994; 14:1767-74.
36. 36. Gianturco SH, Eskin SG, Navarro LT, Lahart CJ, Smith LC, Gotto AM Jr. Abnormal effects of hypertriacylglycerolemic very low-density lipoproteins on 3-hydroxy-3-methylglutaryl-CoA reductase activity and viability of cultured bovine aortic endothelial cells. Biochim Biophys Acta 1980; 618:143-52.
37. 37. Gianturco SH, Ramprasad MP, Song R, Li R, Brown ML, Bradley WA. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol 1998; 18: 968-76.
38. 38. Gianturco SH, Bradley WA. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Clin Cardiol 1999; 22(suppl): 117-14.
39. 39. Gianturco SH, Bradley WA. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia. Semin Thromb Hemost 1988; 14: 165-9.
40. 40. Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-84.
41. 41. Gallin JI, Kaye D, O'Leary WM. Serum lipids in infection. N Engl J Med 1969; 281:1081-6.
42. 42. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90:154-62.
43. 43. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 76:559-65.
44. 44. Feingold KR, Staprans I, Memon RA, et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992; 33:1765-76.
45. 45. Nonogaki K, Moser AH, Pan XM, Staprans I, Grunfeld C, Feingold KR. Lipoteichoic acid stimulates lipolysis and hepatic triglyceride secretion in rats in vivo. J Lipid Res 1995; 36:1987-95.
46. 46. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993; 132:2246-53.
47. 47. Memon RA, Feingold KR, Moser AH, et al. Differential effects of interleukin-1 and tumor necrosis factor on ketogenesis. Am J Physiol 1992; 263:E301-9.
48. 48. Hardardóttir I, Sipe J, Moser AH, Fielding CJ, Feingold KR, Grünfeld C. LPS and cytokines regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochim Biophys Acta 1997; 1344:210-20.
49. 49. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987; 80:184-90.
50. 50. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 1989; 124:2336-42.
51. 51. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989; 125:267-74.
52. 52. Feingold KR, Soued M, Staprans I, et al. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J Clin Invest 1989; 83:1116-21.
53. 53. Feingold KR, Soued M, Adi S, et al. Effect of interleukin-1 on lipid metabolism in the rat. Similarities to and differences from tumor necrosis factor. Arterioscler Thromb 1991; 11:495-500.
54. 54. Krauss RM, Grunfeld C, Doerrler WT, Feingold KR. Tumor necrosis factor acutely increases plasma levels of very low density lipoproteins of normal size and composition. Endocrinology 1990; 127:1016-21.
55. 55. Nonogaki K, Fuller GM, Fuentes NL, et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136:2143-9.
56. 56. Memon RA, Holleran WM, Moser AH, et al. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler Thromb Vasc Biol 1998; 18:1257-65.
57. 57. Redgrave TG, Rakic V, Mortimer BC, Mamo JC. Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerolrich lipoproteins from plasma. Studies with lipid emulsions in rats. Biochim Biophys Acta 1992; 1126:65-72.
58. 58. Memon R, Staprans I, Noor M, et al. Infection and inflammation induce low density lipoprotein oxidation in vivo. Arterioscler Thromb Vasc Biol (in press).
59. 59. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM. Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med 1995; 238:5-20.
60. 60. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272:17895-8.
61. 61. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 1989; 30:305-15.
62. 62. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988; 85:2805-9.
63. 63. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344:160-2.
64. 64. Khovidhunkit W, Memon RA, Shigenaga JK, et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999; 48:1524-31.
65. 65. Pruzanski W, Vadas P, Browning J. Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J Lipid Mediat 1993; 8:161-7.
66. 66. Leitinger N, Watson AD, Hama SY, et al. Role of group II secretory phospholipase A2 in atherosclerosis. 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromh Vase Biol 1999; 19: 1291-8.
67. 67. Ivandic B, Castellani LW, Wang XP, et al. Role of group II secretory phospholipase A2 in atherosclerosis. 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999; 19:1284-90.
68. 68. Feingold KR, Hardardottir I, Memon R, et al. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res 1993; 34:2147-58.
69. 69. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98:1455-64.
70. 70. Marathe S, Schissel SL, Yellin MJ. et al. Human vascular endothelial cells are a rich and regulatuble source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 1998; 273:4081-8.
71. 71. Xu XX, Tabas I, Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. J Biol Chem 1991; 266:24849-58.
72. 72. Memon RA, Holleran WM, Uchida Y, et al. Regulation of glycosphingolipid metabolism in liver during the acute phase response. J Biol Chem 1999; 274:19707-13.
73. 73. Mukhin DN, Chao FF, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler Thromb Vase Biol 1995; 15:1607-15.
74. 74. Chatterjee SB, Dey S, Shi WY, Thomas K, Hutchins GM. Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Glycobiology 1997; 7:57-65.
75. 75. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 1989; 30:39-49.
76. 76. Auerbach BJ, Parks JS. Lipoprotein abnormalities associated with lipopolysaccharide-indueed lecithin: cholesterol acyltransferase and lipase deficiency. J Biol Chem 1989; 264:10264-70.
77. 77. Ettinger WH, Miller LD, Albers JJ, Smith TK, Parks JS. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res 1990; 31:1099-107.
78. 78. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998; 139:307-15.
79. 79. Hardardottir I, Kunitake ST, Moser AH, et al. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest 1994; 94: 1304-9.
80. 80. Hoffman JS, Benditt EP. Changes in high density lipoprotein content following endotoxin administration in the mouse. Formation of serum amyloid protein-rich subfractions. J Biol Chem 1982; 257:10510-7.
81. 81. Ly H, Francone OL, Fielding CJ, et al. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res 1995; 36:1254-63.
82. 82. Hardardóttir I, Moser AH, Fuller J, Fielding C, Feingold K, Grünfeld C. Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in Syrian hamsters. J Clin Invest 1996; 97:2585-92.
83. 83. Feingold KR, Memon RA, Moser AH, Shigenaga JK, Grunfeld C. Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. Atherosclerosis 1999; 142:379-87.
84. 84. Jiang XC, Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem 1995; 270:17133-8.
85. 85. Navab M, Hama SY, Hough GP, et al. High density associated enzymes: their role in vascular biology. Curr Opin Lipidol 1998; 9:449-56.
86. 86. Kunitake ST, Jams MR, Hamilton RL, Kane JP. Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci USA 1992; 89:6993-7.
87. 87. Howard KM, Miller JE, Miwa M, Olson MS. Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver. J Biol Chem 1997; 272:27543-8.
88. 88. Memon RA, Fuller J, Moser AH, Feingold KR, Grunfeld C. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am 3 Physiol 1999; 277:R94-103.
89. 89. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96:2758-67.
90. 90. Castellani LW, Navab M, Lenten BJV, et al. Overexpression of apolipoprotein All in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 1997; 100:464-74.
91. 91. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-7.
92. 92. Samokyszyn VM, Miller DM, Reif DW, Aust SD. Inhibition of Superoxide and ferrilin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem 1989; 264:21-6.
93. 93. Ehrenwald E, Chisolm GM, Fox PL. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 1994; 93:1493-501.
94. 94. Lamb DJ, Leake DS. Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett 1994; 338:122-6.
95. 95. Chisolm GM III, Hazen SL, Fox PL, Cathcart MK. The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms. J Biol Chem 1999; 274:25959-62.
96. 96. Manttari M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994; 15:1599-603.
97. 97. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36:211-28.
98. 98. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996; 37:2473-91.
99. 99. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibei G, Williams DL, Phillips MC. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999; 40:781-96.
100. 100. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABCI in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336-45.
101. 101. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-51.
102. 102. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352-5.
103. 103. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABCI controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25-31.
104. 104. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103:907-14.
105. 105. Johnson WJ, Bamberger MJ, Latta RA, Rapp PE, Phillips MC, Rothblat GH. The bidirectional flux of cholesterol between cells and lipoproteins. Effects of phospholipid depletion of high density lipoprotein. J Biol Chem 1986; 261:5766-76.
106. 106. Hoffman JS, Benditt EP. Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J Clin Invest 1983; 71:926-34.
107. 107. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest 1992; 66:778-85; [erratum] 1992; 67:151.
108. 108. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27:633-45.
109. 109. Tshikawa Y, Akasaka Y, Ishii T, et al. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 1998; 18:665-72.
110. 110. Moulson CL, Millis AJ. Clusterin (Apo J) regulates vascular smooth muscle cell differentiation in vitro. J Cell Physiol 1999; 180:355-64.